BioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 112,400 Shares of Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 112,400 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total value of C$1,267,557.28.

FAX Capital Corp. also recently made the following trade(s):

• On Friday, November 22nd, FAX Capital Corp. sold 230,800 shares of BioSyent stock. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Trading Down 0.8 %

CVE RX opened at C$11.65 on Tuesday. The firm has a market capitalization of C$135.02 million, a PE ratio of 19.42 and a beta of 0.93. BioSyent Inc. has a one year low of C$8.24 and a one year high of C$12.13. The company has a 50-day simple moving average of C$11.30 and a 200-day simple moving average of C$10.66. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.